New drug could reduce Blood-Letting for polycythemia vera patients
NCT ID NCT07429266
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This phase 3 trial tests whether adding the drug sapablursen to standard treatment helps people with polycythemia vera, a blood disorder causing too many red blood cells. About 250 participants who currently need regular blood removal (phlebotomy) will receive either sapablursen or a placebo for up to 156 weeks. The main goal is to see if the drug reduces the need for phlebotomy and improves fatigue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sapablursen (a drug injected under the skin)
What this could lead to
If it works, this could offer a new treatment option to help control polycythemia vera and reduce the need for regular blood removal (phlebotomy).
What could go wrong
This is still an experimental drug, and its safety and effectiveness are not yet proven. Even if successful, it would manage the disease rather than cure it, and long-term risks are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Florida Clinical Trials Group
RECRUITINGPlantation, Florida, 33322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Florida Clinical Trials Group
RECRUITINGTamarac, Florida, 33321, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Gabrail Cancer Center Research
RECRUITINGCanton, Ohio, 44718, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Regis Clinical Research LLC.
RECRUITINGMiami, Florida, 33126, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Center for Cancer & Blood Disorders
RECRUITINGBethesda, Maryland, 20817, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact